Sionna Therapeutics is trading 10.29% up at $7.12, with the move appearing mainly sector-driven as biotech ETF XBI rose 2.75% during regular trading.
- The stock extended its 7.13% gain to $6.46 on September 1.
- No new company-specific announcement or clear catalyst was identified for September 2; latest company news remains the August 6 release.
- Major U.S. indexes were modestly positive; coverage focuses on August’s failed SION-719 trial, related investor investigations, not a new September 2 development.